MDGL Stock Price History and Quote Analysis: Insights for Investors
Madrigal Pharmaceuticals, Inc.
Stock Price Today
Madrigal Pharmaceuticals, Inc. (MDGL) stock surged +0.89%, trading at $208.41 on NASDAQ, up from the previous close of $206.58. The stock opened at $207.69, fluctuating between $205.87 and $209.98 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
West Conshohocken, PA 19428
United States
Website: https://www.madrigalpharma.comContact: 267 824 2827About Company
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Company Information
| Employees | 376 |
| Beta | -0.437 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) stock price is $208.41 in the last trading session. During the trading session, MDGL stock reached the peak price of $209.98 while $205.87 was the lowest point it dropped to. The percentage change in MDGL stock occurred in the recent session was 0.89% while the dollar amount for the price change in MDGL stock was $1.83.
The NASDAQ listed MDGL is part of Biotechnology industry that operates in the broader Healthcare sector. Madrigal Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Thomas W. Hare
Senior Vice President of Clinical Management
Mr. Remy Sukhija
Senior Vice President & Chief Commercial Officer
Mr. Edward Chiang
Senior Vice President of Clinical & Technical Operations
Dr. Rebecca A. Taub M.D.
Founder, Chief Medical Officer, Pres of R&D and Director
Dr. Stephen Dodge M.B.A., Pharm.D.
Senior Vice President of Global Medical Affairs
Dr. Paul A. Friedman M.D.
Chairman & Chief Executive Officer
Dr. Kianoush Motesharei Ph.d.
Senior Vice President of Bus. & Corporation Devel.
Mr. Alex G. Howarth
Senior Vice President & Chief Financial Officer
Dr. Robert E. Waltermire Ph.D.
Chief Pharmaceutical Devel. Officer
Mr. Brian J. Lynch J.D.
Senior Vice President & Gen. Counsel
MDGL's closing price is 74.02% higher than its 52-week low of $119.76 where as its distance from 52-week high of $299.98 is -30.52%.
Number of MDGL employees currently stands at 376.
Official Website of MDGL is: https://www.madrigalpharma.com
MDGL could be contacted at phone 267 824 2827 and can also be accessed through its website. MDGL operates from Four Tower Bridge, West Conshohocken, PA 19428, United States.
MDGL stock volume for the day was 250.33K shares. The average number of MDGL shares traded daily for last 3 months was 270.3K.
The market value of MDGL currently stands at $4.53B with its latest stock price at $208.41 and 21.71M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com